Low-dose aspirin use shows reduced odds of metastatic colorectal cancer in 2026.
This finding comes from a population-based study detailed in Nature, which looked at all patients aged 18 or older diagnosed with primary stage I through IV colorectal cancer in Sweden between 2008 and 2021.
said bioengineer.org.
The study pulled data from the Colorectal Cancer database Sweden (CRCBaSe), linking it with nationwide health and demographic registers using unique personal identification numbers.
For those actively taking prescribed low-dose aspirin, bioengineer.org notes a 14 percent overall reduction in the adjusted odds of synchronous distant metastasis compared to non-users.
This protective association appeared strongest when looking specifically at right-sided colon tumors; bioengineer.org reports a 21 percent reduction in metastatic odds there.
However, the protective link didn’t hold up across the board, as bioengineer.org points out that this association didn’t consistently extend to left-sided colon malignancies.
The analysis used the Swedish Prescribed Drug Register, which tracks dispensations since July 1, 2005, to define low-dose aspirin exposure as a minimum of 365 pills, equivalent to twelve months of use prior to CRC diagnosis.
Researchers carefully accounted for confounding factors, using a directed acyclic graph to guide adjustments for age, sex, education level, diabetes, hypertension, CVD, IBD, and gastrointestinal bleeding, as detailed in Nature.
The human and economic stake here is clear: colorectal cancer is the third most common malignancy globally, with projections anticipating a 71 percent surge in total burden by 2045, according to bioengineer.org.
The Devil’s Advocate perspective exists because randomized trials, like the ASPREE trial, reported an increased risk of incident metastatic cancer among aspirin users, though pooled analyses of earlier prevention trials found a 31 percent reduction in metastatic adenocarcinoma, bioengineer.org reports.
The demographic most affected by this nuance—right-sided vs. left-sided presentation—are those with specific tumor anatomies, a distinction the study made when examining colon versus rectum.
The study detailed in Nature used a cohort of 704 patients with synchronous CRC for the primary outcome assessment.
A key detail for safety and precision is that in Sweden, low-dose aspirin is restricted to medical prescription, preventing untracked over-the-counter acquisition, bioengineer.org states.
“In contrast, this protective association did not consistently extend to left-sided colon malignancies.”
said bioengineer.org. The analysis also explored duration-dependent and dose-dependent effects, including cumulative pill counts, ensuring robustness against simple time-based bias, as detailed in Nature. Global cancer statistics underscore the need for effective, inexpensive preventative strategies when five-year relative survival remains around 60 percent globally, bioengineer.org notes. The rigor of the methodology, including calculating the Charlson Comorbidity Index (CCI) using a five-year look-back for non-malignant conditions, shows a deep commitment to comorbidity burden assessment in the Swedish register data, Nature reports. The ongoing public health discussion must balance this observational data against the conflicting results from clinical trials, especially given the established history of aspirin in cancer biology dating back to 1972 through mouse models, bioengineer.org mentions.
The data on socioeconomic status, proxied by education level (< 10 years, 10-12 years, >12 years), came from the Longitudinal Integrated Database for Health Insurance and Labour Market Studies, Nature confirms. The study confirmed the need to look beyond simple usage time, because the investigation examined the Colorectal Cancer Database Sweden (CRCBaSe) which links the Swedish Colorectal Cancer Registry with nationwide clinical, demographic, and prescription registries, bioengineer.org explains. The complexity of staging, where missing metastasis data in the SCRCR sometimes required cross-checking the National Patient Register (NPR), highlights the intricate data linkage required for accurate oncological staging in large population cohorts, Nature details. The next step for understanding this relationship involves careful stratification by tumor location, specifically right-sided versus left-sided lesions, as shown by bioengineer.org.
Related reading
- Guevarra Surrendered to NBI in Plunder Case With Conditional Immunity
- Chahal Joins BJP, Gets Special Invitee Role in OBC Morcha Committee
- Missouri judge approves $7.25bn Bayer settlement over Roundup cancer claims (newsarchyuk.com)
- EMA Grants Conditional Approval for Daraxonrasib in KRAS G12C Metastatic Pancreatic Cancer (world-today-news.com)